Atopic dermatitis in women: special considerations in the childbearing years
- PMID: 38860232
- PMCID: PMC11164005
- DOI: 10.1097/JW9.0000000000000151
Atopic dermatitis in women: special considerations in the childbearing years
Abstract
Background: Atopic dermatitis (AD) is one of the most common inflammatory dermatoses in adults. Women are disproportionately impacted by AD and report significant impacts on quality of life compared to men.
Objective: Given the absence of formal guidelines for the treatment of AD in women of childbearing age, we will review special considerations for treating women of childbearing age with AD to ensure consistent care and optimal outcomes for these patients.
Methods: PubMed and Google Scholar databases were searched for relevant articles from database inception through May of 2023.
Results: There are several treatments including topical therapies, systemic therapies, and phototherapy that are considered safe during preconception, pregnancy and breastfeeding. Given the negative consequences of uncontrolled AD for both the mother and the unborn baby, the risks and benefits of potential therapies should be reviewed with all women of childbearing age suffering from AD.
Limitations: The gold standard in recommending therapies is randomized controlled trials; however, pregnant and lactating women are often excluded from these trials.
Conclusion: Through shared decision-making between the dermatologist, obstetrician, and patient, the risks and benefits of any therapy should be thoroughly discussed and considered with all women of childbearing age, to optimize care and outcomes for this unique population.
Keywords: atopic dermatitis; inflammation; lactation; pregnancy; treatment; women.
Copyright © 2024 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of Women’s Dermatologic Society.
Conflict of interest statement
The authors made the following disclosures: R.V.: Consultant: McGraw Hill Education. M.S.: Consultant (honoraria): AbbVie, Arcutis, Bristol Myers Squibb, Dermavant, Janssen, Leo Pharma, Lilly USA, Novartis, Novan, Galderma, Ortho Dermatologics, Sanofi-Genzyme, Regeneron, UCB. Speaker: Abbvie, Arcutis, Bristol Myers Squibb, Lilly USA, Janssen, Dermavant, Leo Pharma, Sanofi-Genzyme, Regeneron, UCB. Investigator: AbbVie, CorEvitas Psoriasis Registry, CorEvitas Atopic Dermatitis Registry, Dermira, Lilly USA, Cara, Dermavant, Novartis, Union, Mindera.
References
-
- Zeiser K, Tolkachev V, Schmid-Grendelmeier P; ProRaD Study Group. Sex differences in atopic dermatitis symptom severity - quality of life equally impaired. Cross-sectional results from the ProRaD study. Paper presented at: European Academy of Allergy and Clinical Immunology. July 1, 2022. Available from: www.eaaci.org
-
- Harrop J, Chinn S, Verlato G, et al. Eczema, atopy and allergen exposure in adults: a population-based study. Clin Exp Allergy 2007;37:526–35. - PubMed
LinkOut - more resources
Full Text Sources